• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tevogen Bio Holdings Inc.

    5/1/25 10:46:53 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TVGN alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on May 1, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    Tevogen Bio Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

         
    Delaware   98-1597194
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
         

    15 Independence Boulevard, Suite #410

    Warren, New Jersey 07059

      07059
    (Address of Principal Executive Offices)   (Zip Code)

     

    Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan

    (Full title of the plan)

     

    Ryan Saadi

    Chief Executive Officer

    Tevogen Bio Holdings Inc.

    15 Independence Boulevard, Suite #410

    Warren, New Jersey 07059

    (Name and address of agent for service)

     

    (877) 838-6436

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    William I. Intner

    J. Nicholas Hoover

    Hogan Lovells US LLP

    100 International Drive, Suite 2000

    Baltimore, Maryland 21202

    (410) 659-2700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           
    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Tevogen Bio Holdings Inc. (the “Company”) is filing this registration statement with the Securities and Exchange Commission (the “SEC”) to register the sale and issuance of up to 8,899,568 additional shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), authorized for issuance pursuant to awards under the Company’s 2024 Omnibus Incentive Plan (the “Plan”), pursuant to the provisions of the Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the Plan on January 1, 2025. The Company previously registered the sale of shares of Common Stock under the Plan on a registration statement on Form S-8 filed with the SEC on June 10, 2024 (File No. 333-280075) (the “Prior Registration Statement”).

     

    Pursuant to General Instruction E to Form S-8, this registration statement hereby incorporates by reference the contents of the Prior Registration Statement except as set forth below.

     

    i

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit    
    Number   Description
    4.1   Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on February 14, 2024 (File No. 001-41002))
         
    4.2   Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on April 25, 2025 (File No. 001-41002))
         
    5.1   Opinion of Hogan Lovells US LLP*
         
    23.1   Consent of KPMG LLP, independent registered public accounting firm*
         
    23.2   Consent of Hogan Lovells US LLP (included in Exhibit 5.1)*
         
    24   Power of Attorney (included on signature page)
         
    99.1   Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 filed with the Company’s Current Report on Form 8-K filed on February 14, 2024)
         
    99.2   Form of Restricted Stock Unit Agreement under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No. 333-280075) filed with the SEC on June 10, 2024)
         
    107   Filing Fee Table*

     

    * Filed herewith.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warren, State of New Jersey, on this 1st day of May, 2025.

     

    TEVOGEN BIO HOLDINGS INC.  
         
    By:

    /s/ Ryan Saadi

     
      Ryan Saadi  
      Chief Executive Officer and Chairperson of the Board of Directors  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan Saadi and Kirti Desai, and each of them, such person’s true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and any registration statement relating to the offering covered by this registration statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or such person’s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
         

    /s/ Ryan Saadi

      Chief Executive Officer and Chairperson of the Board of Directors   May 1, 2025
    Ryan Saadi   (Principal Executive Officer)    
         

    /s/ Kirti Desai

      Chief Financial Officer   May 1, 2025
    Kirti Desai   (Principal Financial Officer and Principal Accounting Officer)    
         

    /s/ Jeffrey Feike

      Director   May 1, 2025
    Jeffrey Feike        
         

    /s/ Dr. Keow Lin Goh

      Director   May 1, 2025
    Dr. Keow Lin Goh        
         

    /s/ Dr. Curtis Patton

      Director   May 1, 2025
    Dr. Curtis Patton        
         

    /s/ Susan Podlogar

      Director   May 1, 2025
    Susan Podlogar        
         

    /s/ Victor Sordillo

      Director   May 1, 2025
    Victor Sordillo        

     

    3

     

    Get the next $TVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVGN

    DatePrice TargetRatingAnalyst
    3/4/2025$10.00Buy
    D. Boral Capital
    More analyst ratings

    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saadi Ryan H. gifted 50,000 shares, decreasing direct ownership by 0.04% to 124,284,453 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    12/22/25 5:43:21 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Desai Kirti gifted 300,000 shares, decreasing direct ownership by 3% to 10,149,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    12/15/25 5:31:50 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Saadi Ryan H. gifted 460,000 shares, decreasing direct ownership by 0.37% to 124,334,453 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    12/12/25 6:51:18 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

    WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors aft

    1/30/26 3:00:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

    WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company's long term incentives plan. Tevogen Founder and CEO, Dr. Ryan Saadi, commented, "Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company's goal is

    1/29/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

    Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen's continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications, and advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities. P

    1/12/26 9:00:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/13/24 4:30:24 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/7/24 4:29:51 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Tevogen Bio with a new price target

    D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

    3/4/25 8:26:08 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    SEC Filings

    View All

    Tevogen Bio Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    1/30/26 3:37:38 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Tevogen Bio Holdings Inc.

    DEF 14A - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    1/26/26 5:29:39 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by Tevogen Bio Holdings Inc.

    PRE 14A - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    1/16/26 5:29:28 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Financials

    Live finance-specific insights

    View All

    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

    WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors aft

    1/30/26 3:00:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

    Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

    8/19/25 12:10:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

    WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The

    2/14/25 1:16:54 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

    WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Te

    9/10/25 11:59:02 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/29/25 8:00:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/14/25 1:53:50 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/12/24 4:28:55 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

    SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    3/4/24 4:24:14 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care